



Further to the FTSE notice released on **29 November 2018** in relation to Takeda Pharmaceuticals (Japan): Acquisition of Shire (UK) - Informative Notice, it has been announced that Shire (UK) will move to an un-cleared trading segment on the London Stock Exchange (SETSqx), with effect from Monday 24 December 2018 (open) until the completion of the merger with Takeda Pharmaceuticals. Therefore FTSE Russell intends to implement the event as set out below:

Takeda Pharmaceutical (Japan): Acquisition of Shire (UK)

Informative Notice - Update

14 December 2018

FTSE Russell notes the scheme of arrangement between Shire (UK, B2QKY05, GEIS Large Cap, FTSE 100) and Takeda Pharmaceutical (Japan, 6870445, GEIS Large Cap), whereby Shire shareholder will receive 30.33 USD and 0.839 Takeda Pharmaceutical shares for each share held.

FTSE Russell anticipates the following treatment:

Wednesday 19 December 2018 (at market close):

For the indexes with a fixed number of constituents from which Shire will be deleted (including the FTSE 100 Index), the reserve lists will be ranked based on closing prices, with the highest ranking reserve constituent selected to replace Shire.

Friday 21 December 2018:

Last day of central counterparty clearing (CCP) in Shire shares (i.e. Shire will be removed from LSE SETS order book after market close).

Monday 24 December 2018 (from market open):

Shire will be deleted from the FTSE Russell Indexes concurrent with an associated increase in shares of Takeda Pharmaceutical, and all other index changes (as notified prior) become effective.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2018 FTSE Russell